Skip to content
Triangle logo TriangleGet started
← Study library

NCT01761240 · REGISTRY CONDITION SEARCH

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1
Status at capture
COMPLETED
Registry last update
2024-03-29

This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic, colorectal, and non-small-cell lung cancer (NSCLC) (adenocarcinoma). This open-label study will assess the safety, tolerability, and pharmacokinetics of MORAb-066 administered weekly. This study will identify the maximum tolerated dose (MTD) when MORAb-066 is administered IV once weekly on a 28-day cycle.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

→

outcome · POSTED

Number of Participants With Dose Limiting Toxicity (DLT)

→

outcome · POSTED

Maximum Tolerated Dose (MTD)

→

outcome · POSTED

Cmax: Maximum Observed Serum Concentration for MORAb-066

→

outcome · POSTED

Tmax: Time to Reach Maximum Serum Concentration for MORAb-066

→

outcome · POSTED

t1/2: Terminal Elimination Phase Half-Life for MORAb-066

→

outcome · POSTED

AUC(0-t): Area Under the Serum Concentration-time Curve From Zero Time to the Last Measurable Point for MORAb-066

→

outcome · POSTED

AUC(0-Inf): Area Under the Serum Concentration-time Curve From Zero to Infinity for MORAb-066

→

outcome · POSTED

Vd: Volume of Distribution for MORAb-066

→

outcome · POSTED

CL: Total Body Clearance for MORAb-066

→

outcome · POSTED

Number of Participants With Best Overall Response (BOR)

→

outcome · POSTED

Number of Participants Positive for Antidrug Antibodies (ADA)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: Patients must meet the following criteria in order to be included in this clinical trial: 1. Histologically or cytologically confirmed diagnosis of breast, colorectal, pancreas, or NSCLC (adenocarcinoma) that is metastatic or unresectable for which there is no effective therapy. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 (see Appendix A). 3. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 4. Subject has recovered (to Grade less than or equal to 1) from all clinically significant toxicities related to prior antineoplastic therapies with the exception of alopecia and bone marrow and organ functions (described separately below). 5. Adequate organ system function less than or equal to 2 weeks prior to Day1, defined as follows: * Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10\^9/L * Platelets greater than or equal to 100 x 10\^9/L * Hemoglobin greater than or equal to 9 g/dL * Prothrombin time/partial thromboplastin time (PT/PTT) within institutional limits of normal * Serum total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 3.0 x ULN if no liver involvement or less than or equal to 5 x ULN with liver involvement. * Serum creatinine less than or equal to 1.5 x ULN or calculated creatinine clearance greater than or equal to 50 mL/min as calculated by the Cockcroft-Gault method, OR 24-hour measured urine creatinine clearance greater than or equal to 50 mL/min. 6. Life expectancy of greater than or equal to 12 weeks. 7. Female patients of child-bearing potential (see Appendix C), and all male patients must consent to use a medically acceptable method of contraception throughout the study period and for 30 days after their last MORAb-066 administration. A barrier method of contraception must be included. 8. Patients must be greater than or equal to 18 years of age. 9. Patients entering this study will be asked to provide archival tissue from a previous tumor biopsy (if available) for correlative testing. If tissue is not available, the subject will still be eligible for enrollment into the study. 10. Ability to understand the nature of this study and give written informed consent. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from trial entry: 1. Patients currently receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization). 2. Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of MORAb-066. For investigational drugs for which 5 half-lives is less than 21 days, a minimum of 10 days between termination of the investigational drug and administration of MORAb-066 is required. 3. Any major surgery, chemotherapy, radiotherapy, or immunotherapy within the last 21 days (limited palliative radiation is allowed greater than or equal to 2 weeks). 4. Subject has received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) less than or equal to 28 days or limited field radiation for palliation less than or equal to 14 days prior to starting study drug or has not recovered from side effects of such therapy. 5. Known intracranial involvement, leptomeningeal metastases or spinal cord compression due to disease. 6. Known allergy or hypersensitivity to monoclonal antibodies. 7. Known bleeding diathesis, such as factor deficiency, factor inhibitor, platelet disorder, or who are on active anticoagulation, or any dose of aspirin within 5 days prior to first dose of MORAb-066. 8. Known prior significant bleeding history. 9. Patients with ureteral stents or 3+ blood in the urine at baseline. 10. Patients who are receiving chronic systemic anticoagulation therapy (warfarin sodium or heparin, etc.). 11. Patients who received a previous mAb therapy and have evidence of an immune or allergic reaction or previously documented HAHA reaction. 12. A serious non-healing wound, active ulcer, or untreated bone fracture. An abdominal fistula or gastrointestinal perforation less than 6 months prior to treatment. 13. History of hematemesis or hemoptysis (defined as having bright red blood of 1/2 teaspoon or more per episode) less than or equal to 1 month prior to study enrollment. 14. Subject has cardiac dysfunction including any of the following: * Myocardial infarction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular ejection fraction function * QTcF greater than 470 msec * History of documented congestive heart failure (New York Heart Association functional classification III-IV \[see Appendix B\]) * Angina not well-controlled by medication 15. A serious active infection (bacterial or fungal) at the time of treatment, or another serious underlying medical condition that would impair the ability of the subject to receive protocol treatment. 16. Chronic inflammatory disorder(e.g., inflammatory bowel disease, active vasculitis). 17. Herbal preparations/medications must be discontinued 7 days prior to first dose of study drug (see Section 5.3.1). 18. Known diagnosis of human immunodeficiency virus, Hepatitis B or Hepatitis C. 19. History or current diagnosis of glomerulonephritis 20. History of clinically significant or current diagnosis of hematuria. 21. Women who are pregnant or lactating. 22. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. 23. Concurrent condition that in the investigator's opinion would jeopardize compliance with the protocol. 24. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
healthy Volunteers
false
maximum Age
99 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Participants will receive MORAb-066 0.1 milligram per kilogram (mg/kg), infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
    intervention Names
    1. Drug: MORAb-066
    label
    MORAb-066 0.1 mg/kg
    type
    EXPERIMENTAL
  2. description
    Participants will receive MORAb-066 0.3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
    intervention Names
    1. Drug: MORAb-066
    label
    MORAb-066 0.3 mg/kg
    type
    EXPERIMENTAL
  3. description
    Participants will receive MORAb-066 1 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
    intervention Names
    1. Drug: MORAb-066
    label
    MORAb-066 1 mg/kg
    type
    EXPERIMENTAL
  4. description
    Participants will receive MORAb-066 2 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant's discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
    intervention Names
    1. Drug: MORAb-066
    label
    MORAb-066 2 mg/kg
    type
    EXPERIMENTAL
  5. description
    Participants will receive MORAb-066 3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in each 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.
    intervention Names
    1. Drug: MORAb-066
    label
    MORAb-066 3 mg/kg
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. MORAb-066 0.1 mg/kg
    2. MORAb-066 0.3 mg/kg
    3. MORAb-066 1 mg/kg
    4. MORAb-066 2 mg/kg
    5. MORAb-066 3 mg/kg
    description
    MORAb-066 infusion.
    name
    MORAb-066
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
27
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Safety assessments consisted of monitoring and recording all AEs and SAEs; regular monitoring of hematology, blood chemistry, urine values, and vital signs; periodic measurement of electrocardiograms (ECGs) and Eastern Cooperative Oncology Group (ECOG) assessments; and performance of physical examinations.
    measure
    Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
    time Frame
    First dose of study drug (Baseline) up to 30 days after last dose of study drug (Up to approximately 2 years 7 months)
secondary Outcomes
  1. description
    DLT was defined using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 as any grade 3 or 4 hematemesis, hemoptysis, hematochezia, bright red blood per rectum, epistaxis, gingival bleeding, hemarthrosis, haematuria, uncontrollable menses, or any other bleeding thought to be significant as per assessment of the investigator, regardless of grade.
    measure
    Number of Participants With Dose Limiting Toxicity (DLT)
    time Frame
    Cycle 1 (Cycle length=28 days)
  2. description
    The MTD was defined as the highest dose level at which no more than one out of six participants experienced DLT. DLT was defined using NCI CTCAE Version 4.03 as any grade 3 or 4 hematemesis, hemoptysis, hematochezia, bright red blood per rectum, epistaxis, gingival bleeding, hemarthrosis, haematuria, uncontrollable menses, or any other bleeding thought to be significant as per assessment of the investigator, regardless of grade.
    measure
    Maximum Tolerated Dose (MTD)
    time Frame
    Cycle 1 (Cycle length=28 days)
  3. measure
    Cmax: Maximum Observed Serum Concentration for MORAb-066
    time Frame
    Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)
  4. measure
    Tmax: Time to Reach Maximum Serum Concentration for MORAb-066
    time Frame
    Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)
  5. measure
    t1/2: Terminal Elimination Phase Half-Life for MORAb-066
    time Frame
    Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)
  6. measure
    AUC(0-t): Area Under the Serum Concentration-time Curve From Zero Time to the Last Measurable Point for MORAb-066
    time Frame
    Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)
  7. measure
    AUC(0-Inf): Area Under the Serum Concentration-time Curve From Zero to Infinity for MORAb-066
    time Frame
    Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)
  8. measure
    Vd: Volume of Distribution for MORAb-066
    time Frame
    Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)
  9. measure
    CL: Total Body Clearance for MORAb-066
    time Frame
    Cycle 1 Days 1 and 22: 0-168 hours post-dose (Cycle length=28 days)
  10. description
    BOR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for target and non-target lesions is complete response (CR) or partial response (PR). CR: disappearance of target and non-target lesions, normalization of tumor marker level, all lymph nodes must be non-pathological in size (less than 10 millimeter \[mm\] short axis). PR: at least 30 percent (%) decrease in sum of diameters (SOD) of target lesions, taking as reference the baseline SOD persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
    measure
    Number of Participants With Best Overall Response (BOR)
    time Frame
    Up to approximately 2 years 7 months
  11. measure
    Number of Participants Positive for Antidrug Antibodies (ADA)
    time Frame
    Up to approximately 2 years 7 months
Full study description
brief Summary
This study is a Phase I, first in human, dose-escalation study of MORAb-066, an investigational humanized immunoglobulin G (IgG) monoclonal antibody (mAb) that targets TF-expressing malignancies that include breast, pancreatic, colorectal, and non-small-cell lung cancer (NSCLC) (adenocarcinoma). This open-label study will assess the safety, tolerability, and pharmacokinetics of MORAb-066 administered weekly. This study will identify the maximum tolerated dose (MTD) when MORAb-066 is administered IV once weekly on a 28-day cycle.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-d871fe31babe2a410639
      requested nct id
      NCT01761240
      primary nct id
      NCT01761240
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      payload sha256
      35771efe1f248540b9806aaa9e79456f06d463f8f34d6e55ed19b27252bb4585
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-d871fe31babe2a410639
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT01761240
      occurrences
      1. context exact
        NCT01761240
        end
        11
        exact text
        NCT01761240
        start
        0
      offset unit
      unicode_code_points
      query cond
      Small Intestine Cancer
      query disease state id
      ds-small-intestine-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
      source file sha256
      69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
      source json pointer
      /studies/42/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      daf1b3feb032413964dd3401cffe0e6ea8f8b42c04681b568d6652fdc9f7e76e

    Preserved source evidence · Not medical advice